HBM4003 0.3 mg/kg plus toripalimab 240 mg every 3 week demonstrated manageable safety in solid tumors and no new safety signal. Limited data demonstrated promising antitumor activity, especially in PD-1 treatment-naïve mucosal melanoma.
P1, N=65, Active, not recruiting, Harbour BioMed US, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2023 --> Jun 2022